Edition:
United Kingdom

Aileron Therapeutics Inc (ALRN.OQ)

ALRN.OQ on NASDAQ Stock Exchange Global Market

4.28USD
20 Jul 2018
Change (% chg)

$0.06 (+1.42%)
Prev Close
$4.22
Open
$4.24
Day's High
$4.50
Day's Low
$4.20
Volume
11,447
Avg. Vol
17,300
52-wk High
$15.34
52-wk Low
$4.09

Latest Key Developments (Source: Significant Developments)

Aileron Therapeutics Names John Longenecker As Interim CEO
Tuesday, 15 May 2018 

May 15 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS ANNOUNCES CHANGES TO MANAGEMENT.AILERON THERAPEUTICS INC - JOHN P. LONGENECKER HAS BEEN NAMED INTERIM CHIEF EXECUTIVE OFFICER.AILERON THERAPEUTICS INC - JOSEPH A. YANCHIK III HAS RESIGNED AS PRESIDENT AND CHIEF EXECUTIVE OFFICER AND AS A MEMBER OF CO'S BOARD.  Full Article

Aileron Therapeutics Q1 Loss Per Share $0.52
Wednesday, 9 May 2018 

May 9 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.52.Q1 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S.  Full Article

Aileron Therapeutics Reports Q4 Loss Of $0.47 Per Share
Monday, 2 Apr 2018 

April 2 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.47.Q4 EARNINGS PER SHARE VIEW $-0.44 -- THOMSON REUTERS I/B/E/S.GAAP LOSS PER SHARE $0.47.BELIEVES CASH, CASH EQUIVALENTS, INVESTMENTS AS OF DEC 31 TO ENABLE CO TO FUND OPERATING EXPENSES, CAPEX INTO H2 2019.  Full Article

Aileron Therapeutics posts Q3 loss of $0.45 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aileron Therapeutics Inc :Aileron therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.45.Q3 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Cash, cash equivalents and investments as of Sept. 30, 2017 were $56.9 million, compared to $20.7 million as of December 31, 2016​.Qtrly ‍non-gaap net loss per share attributable to common stockholders $0.43​.  Full Article

BRIEF-Aileron Therapeutics Q1 Loss Per Share $0.52

* AILERON THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS